Literature DB >> 26658686

Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation.

Geun Hong1, Kyung-Suk Suh2, Suk-Won Suh3, Tae Yoo3, Hyeyoung Kim3, Min-Su Park3, YoungRok Choi3, Jin Chul Paeng4, Nam-Joon Yi3, Kwang-Woong Lee3.   

Abstract

BACKGROUND & AIMS: Given the organ shortage for liver transplantation (LT) and the limitations of the current morphology-based selection criteria, improved criteria are needed to achieve the maximum benefit of LT for hepatocellular carcinoma (HCC). We hypothesized that a combination of biological markers may better predict the prognosis than the Milan criteria.
METHODS: HCC patients (n=123) with preoperative data on serum alpha-fetoprotein (AFP) levels and (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) positivity underwent live-donor LT between January 2003 and December 2009. The cut-off values for serum AFP levels (200 ng/ml) and (18)F-FDG PET positivity (1.10) for tumor recurrence were determined by c-statistics using receiver operating characteristic curves. Univariate and multivariate analyses with preoperative variables were performed to find pre-transplant prognostic factors. Disease-free survival rates and overall survival rates were analysed with regard to serum AFP levels and (18)F-FDG PET positivity.
RESULTS: The 5-year disease-free survival rates and overall survival rates were 80.3% and 81.6% respectively. (18)F-FDG PET positivity (hazard ratio (HR) 9.766, 95% CI 3.557-26.816; p<0.001) and serum AFP level (HR 6.234, 95% CI 2.643-14.707; p<0.001) were the only significant pre-transplant prognostic factors in the multivariate analysis; tumor number and size were not significant. A combination of criteria showed that the biologically high-risk group (AFP level ⩾200 ng/ml and PET-positive) had an HR of 29.069 (95% CI 8.797-96.053; p<0.001) compared with the double-negative group. Use of the Milan criteria yielded an HR of 1.351 (95% CI 0.500-3.652; p=0.553).
CONCLUSIONS: The combination of the serum AFP level and (18)F-FDG PET data predicted better outcomes than those using the Milan criteria, improving objectivity when adult-to-adult living donor LT is contemplated.
Copyright © 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alpha-fetoproteins; Biological factors; Fluorodeoxyglucose F18; Hepatocellular carcinoma; Liver transplantation; Living donors; Positron emission tomography

Mesh:

Substances:

Year:  2015        PMID: 26658686     DOI: 10.1016/j.jhep.2015.11.033

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  37 in total

1.  Liver transplantation for hepatocellular carcinoma: pushing the boundaries.

Authors:  Joanne M O'Rourke; Shishir Shetty; Tahir Shah; M Thamara P R Perera
Journal:  Transl Gastroenterol Hepatol       Date:  2019-01-02

Review 2.  Transplantation for hepatocellular cancer: pushing to the limits?

Authors:  Quirino Lai; Alessandro Vitale
Journal:  Transl Gastroenterol Hepatol       Date:  2018-09-14

3.  Baseline and Post-treatment 18F-Fluorocholine PET/CT Predicts Outcomes in Hepatocellular Carcinoma Following Locoregional Therapy.

Authors:  Michael C Wallace; Kenny Sek; Roslyn J Francis; Shaun Samuelson; John Ferguson; Jonathan Tibballs; Ali Asad; David B Preen; Gerry MacQuillan; George Garas; Leon A Adams; Gary P Jeffrey
Journal:  Dig Dis Sci       Date:  2019-08-22       Impact factor: 3.199

4.  Efficacy of contrast-enhanced FDG PET/CT in patients awaiting liver transplantation with rising alpha-fetoprotein after bridge therapy of hepatocellular carcinoma.

Authors:  Rania Refaat; Mohammad Abd Alkhalik Basha; Mohammed Sobhi Hassan; Rasha S Hussein; Ahmed A El Sammak; Dena Abd El Aziz El Sammak; Mohamed Hesham Saleh Radwan; Nahla M Awad; Somaia A Saad El-Din; Engi Elkholy; Dina R D Ibrahim; Shereen A Saleh; Iman F Montasser; Hany Said
Journal:  Eur Radiol       Date:  2018-06-12       Impact factor: 5.315

Review 5.  Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma.

Authors:  Bérénice Charrière; Charlotte Maulat; Bertrand Suc; Fabrice Muscari
Journal:  World J Hepatol       Date:  2016-07-28

6.  Improved performance of Hangzhou criteria for liver transplantation of hepatocellular carcinoma: the role of liver resident FoxP3+ regulatory T cells.

Authors:  Kangjie Chen; Haijun Guo; Shusen Zheng
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

Review 7.  Hepatocellular carcinoma: when is liver transplantation oncologically futile?

Authors:  André Viveiros; Heinz Zoller; Armin Finkenstedt
Journal:  Transl Gastroenterol Hepatol       Date:  2017-07-24

8.  Living donor liver transplantation for hepatocellular carcinoma in Seoul National University.

Authors:  Suk Kyun Hong; Kwang-Woong Lee; Hyo-Sin Kim; Kyung Chul Yoon; Nam-Joon Yi; Kyung-Suk Suh
Journal:  Hepatobiliary Surg Nutr       Date:  2016-12       Impact factor: 7.293

Review 9.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Robin Kate Kelley; Augusto Villanueva; Amit G Singal; Eli Pikarsky; Sasan Roayaie; Riccardo Lencioni; Kazuhiko Koike; Jessica Zucman-Rossi; Richard S Finn
Journal:  Nat Rev Dis Primers       Date:  2021-01-21       Impact factor: 52.329

10.  Gadoxetic acid-enhanced MRI as a predictor of recurrence of HCC after liver transplantation.

Authors:  Sunyoung Lee; Kyoung Won Kim; Woo Kyoung Jeong; Myeong-Jin Kim; Gi Hong Choi; Jin Sub Choi; Gi-Won Song; Sung-Gyu Lee
Journal:  Eur Radiol       Date:  2019-08-30       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.